Assuntos
Cistos/patologia , Fibrose Pulmonar Idiopática/patologia , Mucina-5B/fisiologia , Infecções por Orthomyxoviridae/patologia , Animais , Bleomicina/administração & dosagem , Bleomicina/toxicidade , Coloides , Cistos/induzido quimicamente , Cistos/genética , Cistos/metabolismo , Relação Dose-Resposta a Droga , Esquema de Medicação , Fibrose Pulmonar Idiopática/induzido quimicamente , Fibrose Pulmonar Idiopática/genética , Fibrose Pulmonar Idiopática/metabolismo , Vírus da Influenza A Subtipo H1N1 , Queratina-15/genética , Camundongos , Camundongos Transgênicos , Mucina-5B/biossíntese , Mucina-5B/genética , Infecções por Orthomyxoviridae/genética , Infecções por Orthomyxoviridae/metabolismoRESUMO
The gain-of-function MUC5B promoter variant rs35705950 is the dominant risk factor for developing idiopathic pulmonary fibrosis (IPF). Here we show in humans that MUC5B, a mucin thought to be restricted to conducting airways, is co-expressed with surfactant protein C (SFTPC) in type 2 alveolar epithelia and in epithelial cells lining honeycomb cysts, indicating that cell types involved in lung fibrosis in distal airspace express MUC5B. In mice, we demonstrate that Muc5b concentration in bronchoalveolar epithelia is related to impaired mucociliary clearance (MCC) and to the extent and persistence of bleomycin-induced lung fibrosis. We also establish the ability of the mucolytic agent P-2119 to restore MCC and to suppress bleomycin-induced lung fibrosis in the setting of Muc5b overexpression. Our findings suggest that mucociliary dysfunction might play a causative role in bleomycin-induced pulmonary fibrosis in mice overexpressing Muc5b, and that MUC5B in distal airspaces is a potential therapeutic target in humans with IPF.
Assuntos
Predisposição Genética para Doença , Fibrose Pulmonar Idiopática/genética , Mucina-5B/genética , Mucina-5B/metabolismo , Depuração Mucociliar/genética , Mucosa Respiratória/patologia , Animais , Bleomicina/toxicidade , Modelos Animais de Doenças , Células Epiteliais/metabolismo , Células Epiteliais/patologia , Expectorantes/farmacologia , Expectorantes/uso terapêutico , Feminino , Mutação com Ganho de Função , Humanos , Fibrose Pulmonar Idiopática/induzido quimicamente , Fibrose Pulmonar Idiopática/tratamento farmacológico , Fibrose Pulmonar Idiopática/patologia , Pulmão/citologia , Pulmão/metabolismo , Pulmão/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Depuração Mucociliar/efeitos dos fármacos , Regiões Promotoras Genéticas/genética , Proteína C Associada a Surfactante Pulmonar/metabolismo , Mucosa Respiratória/citologia , Mucosa Respiratória/metabolismoRESUMO
The common gain-of-function MUC5B promoter variant ( rs35705950 ) is the strongest risk factor for the development of idiopathic pulmonary fibrosis (IPF). While the role of complement in IPF is controversial, both MUC5B and the complement system play a role in lung host defense. The aim of this study was to evaluate the relationship between complement component 3 (C3) and MUC5B in patients with IPF and in bleomycin-induced lung injury in mice. To do this, we evaluated C3 gene expression in whole lung tissue from 300 subjects with IPF and 175 healthy controls. Expression of C3 was higher in IPF than healthy controls {1.40-fold increase [95% confidence interval (CI) 1.31-1.50]; P < 0.0001} and even greater among IPF subjects with the highest-risk IPF MUC5B promoter genotype [TT vs. GG = 1.59-fold (95% CI 1.15-2.20); P < 0.05; TT vs. GT = 1.66-fold (95% CI 1.20-2.30); P < 0.05]. Among subjects with IPF, C3 expression was significantly higher in the lung tissue without microscopic honeycombing than in the lung tissue with microscopic honeycombing [1.40-fold increase (95% CI 1.23- 1.59); P < 0.01]. In mice, while bleomycin exposure increased Muc5b protein expression, C3-deficient mice were protected from bleomycin-induced lung injury. In aggregate, our findings indicate that the MUC5B promoter variant is associated with higher C3 expression and suggest that the complement system may contribute to the pathogenesis of IPF.
